Alternative Dosing Regimens for Atezolizumab: An Example of Model-Informed Drug Development in the Postmarketing Setting
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-019-03954-8
Full Text
Open PDFAbstract
Available in full text
Date
September 21, 2019
Authors
Publisher
Springer Science and Business Media LLC